Pharmacologic characterization of wool dust extract in isolated guinea pig trachea.
Wool mill workers develop respiratory symptoms and lung function abnormalities associated with their work in the textile industry. As in other workplaces, which process organic materials, the dust generated in the manufacture of wool has been implicated as a cause of these respiratory problems. Pharmacologic studies of wool dust extract were performed in vitro on guinea pig tracheal (GPT) segments. A wool dust extract (WDE) was prepared from material collected from a mill previously surveyed. When the standardized WDE solution was added to an organ bath in increments of 10, 30, 100, 300, and 1000 microliters it caused a consistent, dose-dependent constriction of GPT. Pretreatment of guinea pig tracheas, prior to WDE challenge, with atropine (10(-6) M), pyrilamine (10(-6) M), indomethacin (10(-6) M), verapamil (10(-6) M), TMBS (10(-6) M), BW755C (10(-6) M) and LY171883 (10(-6) M) was studied in order to evaluate receptor-dependent and -independent characteristics of WDE-induced constriction. WDE-induced bronchoconstriction was partially inhibited by the antihistamine pyrilamine. Atropine and leukotriene inhibitors (LY171883 and BW755C) were not found to have a significant protective effect on WDE-induced constriction. Both TMBS and verapamil (intra- and extracellular calcium blocking agent) suppressed the effect of wool dust extract in the range tested. These findings suggest that in this model, WDE-induced airway constriction is only partly attributable to common mediators of bronchoconstriction (e.g., histamine). The airway effects of WDE may be modulated by calcium channel blocking agents.
Schachter
E N
EN
Mount Sinai School of Medicine, New York, New York 10029-6574,USA.
Zuskin
E
E
Buck
M G
MG
Maayani
S
S
Marom
Z
Z
Goswami
S
S
Rienzi
N
N
D000395:Air Pollutants, Occupational / Q000633:toxicity*; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D016084:Bronchoconstriction / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004391:Dust / Q000009:adverse effects*; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D020024:Leukotriene Antagonists; D008297:Male; D016273:Occupational Exposure; D011738:Pyrilamine / Q000494:pharmacology; D014132:Trachea / Q000187:drug effects* / Q000378:metabolism; D014700:Verapamil / Q000494:pharmacology; D014935:Wool / Q000009:adverse effects*
D000395:Air Pollutants, Occupational; D002121:Calcium Channel Blockers; D016861:Cyclooxygenase Inhibitors; D004391:Dust; D006634:Histamine H1 Antagonists; D020024:Leukotriene Antagonists; D001285:Atropine; D014700:Verapamil; D011738:Pyrilamine; D007213:Indomethacin